Improving Drug Therapy for Pediatric Patients: Unfinished History of Pediatric Drug Development.
作者信息
Ward Robert M
机构信息
University of Utah Department of Pediatrics, Divisions of Clinical Pharmacology and Neonatology.
出版信息
J Pediatr Pharmacol Ther. 2023;28(1):4-9. doi: 10.5863/1551-6776-28.1.4. Epub 2023 Feb 3.
Abstract
摘要
相似文献
1
Improving Drug Therapy for Pediatric Patients: Unfinished History of Pediatric Drug Development.改善儿科患者的药物治疗：儿科药物研发的未竟历程。
J Pediatr Pharmacol Ther. 2023;28(1):4-9. doi: 10.5863/1551-6776-28.1.4. Epub 2023 Feb 3.
2
The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More.儿科药物研发与使用的变革：不再是治疗孤儿药
J Pediatr Pharmacol Ther. 2020;25(7):565-573. doi: 10.5863/1551-6776-25.7.565.
3
Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?《儿童最佳药品法案》及《儿科研究公平法案》综述：产科界能从儿科经验中学到什么？
Semin Perinatol. 2015 Nov;39(7):530-1. doi: 10.1053/j.semperi.2015.08.006. Epub 2015 Oct 9.
4
The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective.《最佳儿童药物法案》和《儿科研究公平法案》成年-肿瘤学视角。
Pediatr Blood Cancer. 2021 Mar;68(3):e28871. doi: 10.1002/pbc.28871. Epub 2020 Dec 31.
5
Ethical Considerations for Pediatric Placebo-Controlled Trials: FDA Outcomes and Perspectives.儿科安慰剂对照试验的伦理考虑：FDA 的结果和观点。
Ther Innov Regul Sci. 2021 Mar;55(2):282-303. doi: 10.1007/s43441-020-00214-3. Epub 2020 Sep 8.
6
Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.美国儿科研究公平法案下强制性儿科上市后研究的完成率和报告情况。
JAMA Pediatr. 2019 Jan 1;173(1):68-74. doi: 10.1001/jamapediatrics.2018.3416.
7
8
Clinical trials in neonates: a therapeutic imperative.新生儿临床试验：治疗的迫切需求。
Clin Pharmacol Ther. 2009 Dec;86(6):585-7. doi: 10.1038/clpt.2009.207.
9
Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis.支持儿童安全有效使用治疗药物的儿科药物政策：系统分析
Health Aff (Millwood). 2020 Oct;39(10):1799-1805. doi: 10.1377/hlthaff.2020.00198.
10
Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.根据《儿童最佳药物法案》授予独家销售权的药物的安全性监测：美国食品药品监督管理局所了解到的情况。
Clin Pharmacol Ther. 2007 Aug;82(2):133-4. doi: 10.1038/sj.clpt.6100285.
引用本文的文献
1
Exploring the interconnected properties of cannabidiol suspensions and orodispersible films.探索大麻二酚悬浮液和口腔崩解膜的相互关联特性。
Sci Rep. 2025 Jul 1;15(1):21564. doi: 10.1038/s41598-025-02859-2.
2
Commentary: The Injustice of Paediatric Drug Labelling in Canada - A Call to Action.评论：加拿大儿科药物标签的不公正——行动呼吁。
Healthc Policy. 2023 Aug;19(1):65-70. doi: 10.12927/hcpol.2023.27156.
本文引用的文献
1
Drug labeling and exposure in neonates.新生儿的药物标签和暴露情况。
JAMA Pediatr. 2014 Feb;168(2):130-6. doi: 10.1001/jamapediatrics.2013.4208.
2
The Elixir Sulfanilamide-Massengill.万灵磺胺酏剂 - 马森吉尔公司产品
Can Med Assoc J. 1937 Dec;37(6):590.
3
ON THE MODE OF ACTION OF SULFANILAMIDE IN EXPERIMENTAL STREPTOCOCCUS EMPYEMA.磺胺在实验性链球菌性脓胸中的作用方式。
J Exp Med. 1937 Oct 31;66(5):535-48. doi: 10.1084/jem.66.5.535.
4
ELIXIR SULFANILAMIDE-MASSENGILL: Report of the United States Secretary of Agriculture.伊克赛锭磺胺米施尼来姆：美国农业部长的报告。
Cal West Med. 1938 Jan;48(1):68-70.
5
Thalidomide--a lesson in remote effects of drugs.沙利度胺——药物远期效应的一个教训。
Am J Dis Child. 1962 Aug;104:111-3. doi: 10.1001/archpedi.1962.02080030113001.
6
A study of the German outbreak of phocomelia. The thalidomide syndrome.一项关于德国短肢畸形爆发的研究。沙利度胺综合征。
JAMA. 1962 Jun 30;180:1106-14.
7
An update on the therapeutic orphan.治疗孤儿药的最新情况。
Pediatrics. 1999 Sep;104(3 Pt 2):585-90.
8
9
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.酏剂、稀释剂与1938年《联邦食品、药品和化妆品法案》的通过
Ann Intern Med. 1995 Mar 15;122(6):456-61. doi: 10.7326/0003-4819-122-6-199503150-00009.
10
Therapeutic orphans.
J Pediatr. 1968 Jan;72(1):119-20. doi: 10.1016/s0022-3476(68)80414-7.
Zotero 插件